{
  "docId": "019de517-44b3-71b5-8a8d-243b41bb1797",
  "docSlug": "c77cf9536b998c2f906519be4212f807",
  "documentTitle": "GH Research | Investor Presentation Deck | 30 slides",
  "authorId": "gh-research",
  "authorName": "GH Research",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 7,
  "pageCount": 30,
  "prevPage": 6,
  "nextPage": 8,
  "slideType": "product_demo",
  "function": "present_solution",
  "density": "dense",
  "nDataPoints": 0,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de517-44b3-71b5-8a8d-243b41bb1797/7",
  "deckHref": "/decks/019de517-44b3-71b5-8a8d-243b41bb1797",
  "deckJsonHref": "/decks/019de517-44b3-71b5-8a8d-243b41bb1797.json",
  "deckAnchorHref": "/decks/019de517-44b3-71b5-8a8d-243b41bb1797#slide-7",
  "components": [
    {
      "bbox": {
        "h": 0.02,
        "w": 0.097,
        "x": 0.657,
        "y": 0.702
      },
      "kind": "callout",
      "text": "Foundational IP",
      "attrs": {},
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "df92820c-091b-4674-9136-0c130a25a718",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.355,
        "w": 0.205,
        "x": 0.767,
        "y": 0.516
      },
      "kind": "image",
      "text": "WIPO PCT\nWO 2020/169850 A1\nWIPO PCT\nWO 2020/169851 A1\nWIPO PCT\nWO 2021/170614 A1\nWIPO PCT\nWO 2020/254584 A1",
      "attrs": {},
      "subkind": "icon-grid",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3c3275a1-d61a-4eef-827c-228d0198d049",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.279,
        "w": 0.18,
        "x": 0.774,
        "y": 0.165
      },
      "kind": "image",
      "text": "Mebufotenin (5-MeO-DMT)",
      "attrs": {},
      "subkind": "illustration",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "847145b3-ada3-4d63-b8af-6198835e0f07",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.349,
        "w": 0.65,
        "x": 0.071,
        "y": 0.472
      },
      "kind": "list",
      "text": "GH001 (Mebufotenin administration via a proprietary pulmonary inhalation approach)\nPsychoactive effects with ultra-rapid onset (within seconds) and short duration (5 to 30 min)\nHigh propensity to induce peak experiences (PE), which may be a surrogate marker for therapeutic effects\nIntraday individualized dosing regimen (IDR) for maximization of ultra-rapid and durable remissions\nSingle visit initial treatment, with no structured psychotherapy\nPotential for convenient and infrequent retreatment",
      "attrs": {},
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2d1e8313-27e5-4872-8d0a-d42b2f7090ba",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.137,
        "w": 0.518,
        "x": 0.071,
        "y": 0.24
      },
      "kind": "list",
      "text": "Mebufotenin (5-Methoxy-N,N-Dimethyltryptamine, 5-MeO-DMT)\nNaturally-occurring psychoactive substance from tryptamine class\nHighly potent agonist on 5-HT1A and 5-HT2A receptors",
      "attrs": {},
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ae8df05b-60b6-46db-b49e-1ce2549d5a84",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.015,
        "w": 0.139,
        "x": 0.038,
        "y": 0.94
      },
      "kind": "source-note",
      "text": "2023© GH Research PLC",
      "attrs": {},
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "07bf4368-8092-4224-a5ca-ceb7b8339298",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.603,
        "x": 0.071,
        "y": 0.101
      },
      "kind": "title",
      "text": "Mebufotenin (5-MeO-DMT) and GH001",
      "attrs": {},
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ef862b5e-9b97-4d15-8bad-9a374e15388f",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 8,
      "from": 7,
      "beatId": "0d87c0d2-b899-48a3-a1fc-69055d27d0d9",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Solution",
      "beatSlug": "sequoia-pitch-solution",
      "evidence": "Slides 7-8 introduce the solution and GH001",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [
    {
      "to": 30,
      "from": 5,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "e59b812c-5781-40d1-880d-5eb666da502e",
      "evidence": "The document emphasizes the limitations of current treatments and the potential of GH001",
      "position": 0,
      "objective": "Highlight the need for more effective depression treatments",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    },
    {
      "to": 30,
      "from": 3,
      "name": "Golden Circle",
      "slug": "11-golden-circle",
      "bestFor": "Visionary leadership, brand positioning, mission statements",
      "matchId": "a0a779b4-6b2d-4f03-ae8f-5683cc3e54fa",
      "evidence": "The document presents a clear 'why' for GH001, highlighting its potential to provide ultra-rapid, durable remissions",
      "position": 1,
      "objective": "Explain why GH001 is a necessary solution",
      "structure": "The Why (Belief) -> The How (Process) -> The What (Result)",
      "confidence": 0.6,
      "description": "Invert the typical pitch by starting with why you exist, rather than what you do"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}